Completed PHASE2 INTERVENTIONAL NCT00161889

FSME IMMUN NEW Follow-up to Study 205 in Children Aged 6 to 16 Years

Follow-up Study to Investigate the Safety and Immunogenicity of a Third Vaccination With Three Different Antigen Concentrations of FSME IMMUN NEW in Children Aged 6 to 16 Years

Sponsor: Pfizer

Conditions Encephalitis, Tick-borne

Interventions Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)

Updated 6 times since 2017 Last updated: May 20, 2015 Started: Feb 28, 2002 Completion: Aug 31, 2002

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Encephalitis, Tick-borne and is currently completed. Pfizer leads this study, which shows 6 recorded versions since 2002 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Feb 2002

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Pfizer

Data source: Pfizer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Augsburg, Germany , Bad Saulgau, Germany , Bietigheim-Bissingen, Germany , Calw, Germany , Coburg, Germany , Elzach, Germany , Ettenheim, Germany , Gersfeld, Germany , Heilbronn, Germany , Kehl, Germany and 9 more locations